Company and Stock Identity

How Nanox.AI Connects to the Public Market

Company structure
Nano-X Imaging product line
Market access
Public parent: Nano-X Imaging, Nasdaq: NNOX.
Stock name
Nano-X Imaging Ltd.
Ticker and exchange
Nasdaq: NNOX
Research focus
Separate the AI analytics business from Nano-X Imaging as a whole, and check how many findings each cleared product adds on routine scans, how often a flagged finding changes care, and the false alert load on radiologists.

Nanox.AI is the AI division of Nano-X Imaging Ltd. It was Zebra Medical Vision until Nano-X Imaging completed the merger on November 4, 2021 and rebranded it Nanox.AI, so older FDA records are filed under Zebra Medical Vision, Ltd.

Dated Market Snapshot

Oct 8, 2026

Last price
$0.5378
Change
-5.03%
Previous close
$0.5663
52-week high / low
$4.705/$0.55
Market cap
42,264,970

Automated from Nasdaq. Check the exchange or investor-relations page for the current price.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

No dated update is in the editorial file yet. Use the verified company sources below and check the profile verification date before relying on an older announcement.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Medical imaging AI, data science, clinical and regulatory work, and the engineering behind population-health screening on routine CT.

Qualification signal: Imaging informatics, clinical validation, and medical-device software experience matter more here than a general AI certificate, because the products are regulated and read real patient scans.

Check current roles at Nanox.AI. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Nanox.AI appears on 6 cleared products in the federal 510(k) record, across 2 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources